Patients with neuroendocrine tumors (NETs) may experience fewer symptoms and survive longer by undergoing peptide-receptor radionuclide therapy (PRRT) combined with a drug that makes tumor cells more sensitive to radiation therapy, say researchers.
Patients with neuroendocrine tumors (NETs) may experience fewer symptoms and survive longer by undergoing peptide-receptor radionuclide therapy (PRRT) combined with a drug that makes tumor cells more sensitive to radiation therapy, say researchers.